The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $12.53 in the prior trading day, Hims & Hers Health Inc (NYSE: HIMS) closed at $12.51, down -0.16%. In other words, the price has decreased by -$0.16 from its previous closing price. On the day, 4.81 million shares were traded. HIMS stock price reached its highest trading level at $13.16 during the session, while it also had its lowest trading level at $12.185.
Ratios:
Our goal is to gain a better understanding of HIMS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 57.04. For the most recent quarter (mrq), Quick Ratio is recorded 2.74 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on April 16, 2024, Downgraded its rating to Hold and sets its target price to $15 from $17 previously.
On April 10, 2024, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $20.
Imperial Capital Upgraded its In-line to Outperform on February 28, 2024, while the target price for the stock was maintained at $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 29 ’24 when Boughton Soleil sold 2,503 shares for $12.56 per share. The transaction valued at 31,438 led to the insider holds 161,860 shares of the business.
Boughton Soleil sold 2,503 shares of HIMS for $34,917 on Apr 15 ’24. The Chief Legal Officer now owns 164,363 shares after completing the transaction at $13.95 per share. On Apr 08 ’24, another insider, Baird Melissa, who serves as the Chief Operating Officer of the company, sold 11,751 shares for $14.74 each. As a result, the insider received 173,254 and left with 538,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 2685259008 and an Enterprise Value of 2469238528. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.07 while its Price-to-Book (P/B) ratio in mrq is 7.76. Its current Enterprise Value per Revenue stands at 2.832 whereas that against EBITDA is -149.714.
Stock Price History:
The Beta on a monthly basis for HIMS is 0.96, which has changed by 0.066496134 over the last 52 weeks, in comparison to a change of 0.23568535 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $17.16, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is -8.95%, while the 200-Day Moving Average is calculated to be 35.97%.
Shares Statistics:
The stock has traded on average 5.12M shares per day over the past 3-months and 3539800 shares per day over the last 10 days, according to various share statistics. A total of 205.10M shares are outstanding, with a floating share count of 139.59M. Insiders hold about 34.85% of the company’s shares, while institutions hold 38.57% stake in the company. Shares short for HIMS as of 1713139200 were 17468335 with a Short Ratio of 3.41, compared to 1710460800 on 12762013. Therefore, it implies a Short% of Shares Outstanding of 17468335 and a Short% of Float of 10.93.
Earnings Estimates
Hims & Hers Health Inc (HIMS) is currently under the scrutiny of 10.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.03 and a low estimate of -$0.04, while EPS last year was -$0.05. The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.14 and -$0.11 for the fiscal current year, implying an average EPS of $0.06. EPS for the following year is $0.21, with 11.0 analysts recommending between $0.35 and $0.02.
Revenue Estimates
11 analysts predict $270.38M in revenue for the current quarter. It ranges from a high estimate of $271.65M to a low estimate of $268.9M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $190.77MFor the next quarter, 11 analysts are estimating revenue of $288.07M. There is a high estimate of $291.91M for the next quarter, whereas the lowest estimate is $284.6M.
A total of 13 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $1.2B, while the lowest revenue estimate was $1.18B, resulting in an average revenue estimate of $1.19B. In the same quarter a year ago, actual revenue was $878MBased on 13 analysts’ estimates, the company’s revenue will be $1.48B in the next fiscal year. The high estimate is $1.56B and the low estimate is $1.42B.
